Page 516 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

474 MEDICAMENT INDUISANT OUSTABILISANT DES COUPURES DE LADN

FISHER G.R., PATTERSON L.H., DNA strand breakage by peroxidase-activated
mitoxantrone, J. Pharm. Pharmacol., 1991, 43, 65-68.
HO C.-K. et al., Inhibition of microtubule assembly is a possible mechanism of action of
mitoxantrone, Biochem. Biophys. Res. Commun., 1991, 180, 118-123.
FISHER G.R., PATTERSON L.H., Lack of involvement of reactive oxygen in the cytotoxi-
city of mitoxantrone, CI 941 and ametantrone in MCF-7 cells : comparison with doxo-
rubicin, Cancer Chemother. Pharmaco/., 1992, 30, 451-458.
FISCHER G.R. et al., NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-
mediated two-electron reduction of anthraquinone-based antitumour agents and
generation of hydroxyl radicals, Biochem. Pharmacol., 1992, 43, 575-585.
DE ISABELLA P. et al., Sequence selectivity of topoisomerase Il DNA cleavage stimula-
ted by mitoxantrone derivatives : relationships to drug DNA binding and cellular
effects, Mo/ecular Pharmacology, 1993, 43, 715-721.
MEWES K. et a/., Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation
of electrophilic intermediates, Cancer Res., 1993, 53, 5135-5142.
MEWES K. et al., Synthese and structural elucidation of biliary excreted thioether deri-
vatives of mitoxantrone, Xenobiotica, 1994, 24, 199-213.
PANOUSIS C., PHILLIPS D.R., DNA sequence specificity of mitoxantrone, Nuc/eic Acids
Res., 1994, 22, 1342-1345.
PANOUSIS C. et a/., Oxidative metabolism of mitoxantrone by the human neutrophil
enzyme myeloperoxidase, Biochem. Pharmacol., 1994, 48, 2223-2230.
ZELLER K.-P. et al., Formation of reactive intermediates by cytochrome P-450 mediated
oxidation of the anti-cancer drug mitoxantrone, Pure and Appl. Chem., 1994, 66,
2415-2418.
PANOUSIS C. et al., Myeloperoxidase oxidizes mitoxantrone to metabolites which bind
covalently to DNA and RNA, Anti-Cancer Drug Des., 1995, 10, 593-605.
BAILLY C. et al., DNA recognition by two mitoxantrone analogues : influence of the
hydroxyl groups, FEBS Lett., 1996, 379, 269-272.
CORNAROTTI M. et al., Drug sensitivity and sequence specificity of human recombinant
DNA topoisomerases lla (p170) and II~ (p180), Mol. Pharmacol., 1996, 50, 1463-1471.
FUNABIKI T., Drug resistance of human lymphocytic leukemia cell induced by alteration
of topoisomerase 11, Yokohama lgaku, 1996, 47, 665-673 ; Chem. Abstr., 1997, 126,
287723.
REHN C., PINDUR U., Model building and molecular mechanics calculations of mitoxan-
trone-deoxytetranucleotide complexes : molecular foundations of DNA, intercalation
as cytotoxic active principle, Monatshefte fur chemie, 1996, 127, 631-644.
WITHOFF S. et al., Differential expression of DNA topoisomerase lla and -B in P-gp and
MRP- negative VM26, mAMSA and mitoxantrone-resistant sublines of the human
SCLC cell line GLC,, Br. J. Cancer, 1996, 74 (12), 1869-1876.
HERMAN E. H. et al., Comparison of the structural changes induced by doxorubicin and
mitoxantrone in the heart, kidney and intestine and characterization of the Fe(llI)-
mitoxantrone complex, J. Mol. Cell. Cardiol., 1997, 29, 2415-2430.
PANOUSIS C. et al., Neutrophil-mediated activation of mitoxantrone to metabolites
which form adducts with DNA, Cancer Lett., 1997, 113, 173-178.
TRANCHAND B., Guide pratique de pharmacocinétique clinique en oncologie (1997),
Éditions Frison-Roche, Paris.